Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Plasticity of Type I Interferon-Mediated Responses in Cancer Therapy: From Anti-tumor Immunity to Resistance
Authors
Keywords
-
Journal
Frontiers in Oncology
Volume 8, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-08-21
DOI
10.3389/fonc.2018.00322
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Evidence for the ISG15-Specific Deubiquitinase USP18 as an Antineoplastic Target
- (2018) Lisa Maria Mustachio et al. CANCER RESEARCH
- Signalling mechanism(s) of epithelial–mesenchymal transition and cancer stem cells in tumour therapeutic resistance
- (2018) Zhihong Cai et al. CLINICA CHIMICA ACTA
- Oncorine, the World First Oncolytic Virus Medicine and its Update in China
- (2018) Min Liang CURRENT CANCER DRUG TARGETS
- Negative regulation of type I IFN signaling
- (2018) Kei-Ichiro Arimoto et al. JOURNAL OF LEUKOCYTE BIOLOGY
- Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model
- (2017) Shekhar K. Gadkaree et al. HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK
- CAR T-cell therapy of solid tumors
- (2017) Carmen S M Yong et al. IMMUNOLOGY AND CELL BIOLOGY
- Drug Resistance Driven by Cancer Stem Cells and Their Niche
- (2017) Marta Prieto-Vila et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Regulation of type I interferon signaling in immunity and inflammation: A comprehensive review
- (2017) Kun Chen et al. JOURNAL OF AUTOIMMUNITY
- New development in CAR-T cell therapy
- (2017) Zhenguang Wang et al. Journal of Hematology & Oncology
- Ruxolitinib and Polycation Combination Treatment Overcomes Multiple Mechanisms of Resistance of Pancreatic Cancer Cells to Oncolytic Vesicular Stomatitis Virus
- (2017) Sébastien A. Felt et al. JOURNAL OF VIROLOGY
- Tumour heterogeneity and resistance to cancer therapies
- (2017) Ibiayi Dagogo-Jack et al. Nature Reviews Clinical Oncology
- Overexpression of Interferon Regulatory Factor 7 (IRF7) Reduces Bone Metastasis of Prostate Cancer Cells in Mice
- (2017) Yang Zhao et al. ONCOLOGY RESEARCH
- Interferon-beta represses cancer stem cell properties in triple-negative breast cancer
- (2017) Mary R. Doherty et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells
- (2017) Jeffrey J. Rodvold et al. Science Signaling
- 6-Hydroxy-3- O -methyl-kaempferol 6- O -glucopyranoside potentiates the anti-proliferative effect of interferon α/β by promoting activation of the JAK/STAT signaling by inhibiting SOCS3 in hepatocellular carcinoma cells
- (2017) Orawan Wonganan et al. TOXICOLOGY AND APPLIED PHARMACOLOGY
- Type I Interferon in Chronic Virus Infection and Cancer
- (2017) Laura M. Snell et al. TRENDS IN IMMUNOLOGY
- Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
- (2017) Scott Gettinger et al. Cancer Discovery
- Immunomodulatory and antitumor effects of type I interferons and their application in cancer therapy
- (2017) Ruan F.V. Medrano et al. Oncotarget
- PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity
- (2017) Maria Gato-Cañas et al. Cell Reports
- CD95/Fas Increases Stemness in Cancer Cells by Inducing a STAT1-Dependent Type I Interferon Response
- (2017) Abdul S. Qadir et al. Cell Reports
- Intercellular transmission of the unfolded protein response promotes survival and drug resistance in cancer cells
- (2017) Jeffrey J. Rodvold et al. Science Signaling
- A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice
- (2017) Jeremy B. Foote et al. Cancer Immunology Research
- Durable response rate as an endpoint in cancer immunotherapy: insights from oncolytic virus clinical trials
- (2017) Howard L. Kaufman et al. Journal for ImmunoTherapy of Cancer
- Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial
- (2016) T. K. Eigentler et al. ANNALS OF ONCOLOGY
- Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
- (2016) Xiaohong Wang et al. CANCER RESEARCH
- Loss of IFN-γ Pathway Genes in Tumor Cells as a Mechanism of Resistance to Anti-CTLA-4 Therapy
- (2016) Jianjun Gao et al. CELL
- Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade
- (2016) Joseph L. Benci et al. CELL
- SOCS1 in cancer: An oncogene and a tumor suppressor
- (2016) Claudia Beaurivage et al. CYTOKINE
- Half-life extended biotherapeutics
- (2016) Roland E. Kontermann EXPERT OPINION ON BIOLOGICAL THERAPY
- Small Molecule Agonists for the Type I Interferon Receptor: AnIn SilicoApproach
- (2016) Lianhu Wei et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- STAT1 and NF- B Inhibitors Diminish Basal Interferon-Stimulated Gene Expression and Improve the Productive Infection of Oncolytic HSV in MPNST Cells
- (2016) J. D. Jackson et al. MOLECULAR CANCER RESEARCH
- Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
- (2016) Jesse M. Zaretsky et al. NEW ENGLAND JOURNAL OF MEDICINE
- Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
- (2016) Daniel Sanghoon Shin et al. Cancer Discovery
- Phospholipid scramblase 1 as a critical node at the crossroad between autophagy and apoptosis in mantle cell lymphoma
- (2016) Katy Mastorci et al. Oncotarget
- Intracellular STING inactivation sensitizes breast cancer cells to genotoxic agents
- (2016) Julie Gaston et al. Oncotarget
- Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and Progression
- (2016) Yuliya V. Katlinskaya et al. Cell Reports
- Into the clinic: Talimogene laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy
- (2016) Hasan Rehman et al. Journal for ImmunoTherapy of Cancer
- NF-κB and IRF pathways: cross-regulation on target genes promoter level
- (2015) Marta Iwanaszko et al. BMC GENOMICS
- Activation of IFN/STAT1 signalling predicts response to chemotherapy in oestrogen receptor-negative breast cancer
- (2015) Marie-Emmanuelle Legrier et al. BRITISH JOURNAL OF CANCER
- The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant
- (2015) Kobe Reynders et al. CANCER TREATMENT REVIEWS
- Molecular Pathways: Targeting the Stimulator of Interferon Genes (STING) in the Immunotherapy of Cancer
- (2015) L. Corrales et al. CLINICAL CANCER RESEARCH
- Receptor dimerization dynamics as a regulatory valve for plasticity of type I interferon signaling
- (2015) Stephan Wilmes et al. JOURNAL OF CELL BIOLOGY
- Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis
- (2015) Marlena M. Westcott et al. JOURNAL OF VIROLOGY
- Discontinuation of alpha-interferon treatment in patients with chronic myeloid leukemia in long-lasting complete molecular response
- (2015) Roberto Latagliata et al. LEUKEMIA & LYMPHOMA
- Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer
- (2015) Christina Twyman-Saint Victor et al. NATURE
- The future of immune checkpoint therapy
- (2015) P. Sharma et al. SCIENCE
- Phase I Study of OPB-31121, an Oral STAT3 Inhibitor, in Patients with Advanced Solid Tumors
- (2015) Do-Youn Oh et al. Cancer Research and Treatment
- Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity
- (2015) Leticia Corrales et al. Cell Reports
- Loss of Host Type-I IFN Signaling Accelerates Metastasis and Impairs NK-cell Antitumor Function in Multiple Models of Breast Cancer
- (2015) J. Rautela et al. Cancer Immunology Research
- Combination of the oral histone deacetylase inhibitor resminostat with oncolytic measles vaccine virus as a new option for epi-virotherapeutic treatment of hepatocellular carcinoma
- (2015) Benjamin Ruf et al. Molecular Therapy-Oncolytics
- Fine Tuning of a Type 1 Interferon Antagonist
- (2015) Victoria Urin et al. PLoS One
- Inhibition of the JAK/STAT pathway with ruxolitinib overcomes cisplatin resistance in non-small-cell lung cancer NSCLC
- (2014) Yuan Hu et al. APOPTOSIS
- Exosome Transfer from Stromal to Breast Cancer Cells Regulates Therapy Resistance Pathways
- (2014) Mirjam C. Boelens et al. CELL
- STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors
- (2014) Seng-Ryong Woo et al. IMMUNITY
- STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors
- (2014) Liufu Deng et al. IMMUNITY
- PEGylation Improves the Pharmacokinetic Properties and Ability of Interferon Gamma to Inhibit Growth of a Human Tumor Xenograft in Athymic Mice
- (2014) Christine M. Fam et al. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH
- Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
- (2014) Antonella Sistigu et al. NATURE MEDICINE
- Genetic Engineering of Hematopoiesis for Targeted IFN- Delivery Inhibits Breast Cancer Progression
- (2014) G. Escobar et al. Science Translational Medicine
- Interferons and Their Stimulated Genes in the Tumor Microenvironment
- (2014) HyeonJoo Cheon et al. SEMINARS IN ONCOLOGY
- CD95 and CD95L promote and protect cancer stem cells
- (2014) Paolo Ceppi et al. Nature Communications
- Engineered tumor-infiltrating macrophages as gene delivery vehicles for interferon-α activates immunity and inhibits breast cancer progression
- (2014) Giulia Escobar et al. OncoImmunology
- Overcoming cancer cell resistance to VSV oncolysis with JAK1/2 inhibitors
- (2013) D Escobar-Zarate et al. CANCER GENE THERAPY
- Type I interferons induced by radiation therapy mediate recruitment and effector function of CD8+ T cells
- (2013) Joanne Y. H. Lim et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Fine tuning type I interferon responses
- (2013) Paul J. Hertzog et al. CYTOKINE & GROWTH FACTOR REVIEWS
- IFNβ-dependent increases in STAT1, STAT2, and IRF9 mediate resistance to viruses and DNA damage
- (2013) HyeonJoo Cheon et al. EMBO JOURNAL
- Recognition of cytosolic DNA by cGAS and other STING-dependent sensors
- (2013) Numana Bhat et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- STAT3 inhibition sensitizes colorectal cancer to chemoradiotherapyin vitroandin vivo
- (2013) Melanie Spitzner et al. INTERNATIONAL JOURNAL OF CANCER
- Severe adverse events from the treatment of advanced melanoma: a systematic review of severe side effects associated with ipilimumab, vemurafenib, interferon alfa-2b, dacarbazine and interleukin-2
- (2013) Chelsea Ma et al. JOURNAL OF DERMATOLOGICAL TREATMENT
- Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
- (2013) Omid Hamid et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pegylated Interferon-α2a Inhibits Proliferation of Human Liver Cancer Cells In Vitro and In Vivo
- (2013) Hironori Kusano et al. PLoS One
- Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia
- (2012) A. Eghtedar et al. BLOOD
- Cancer Stem Cells: Impact, Heterogeneity, and Uncertainty
- (2012) Jeffrey A. Magee et al. CANCER CELL
- LY294002 inhibits TLR3/4-mediated IFN-β production via inhibition of IRF3 activation with a PI3K-independent mechanism
- (2012) Wei Zhao et al. FEBS LETTERS
- Vesicular Stomatitis Virus as an Oncolytic Agent against Pancreatic Ductal Adenocarcinoma
- (2012) A. M. Murphy et al. JOURNAL OF VIROLOGY
- Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape
- (2012) Bradley N Bidwell et al. NATURE MEDICINE
- Anti-tumorigenic effects of Type 1 interferon are subdued by integrated stress responses
- (2012) S Bhattacharya et al. ONCOGENE
- Expression Signature of IFN/STAT1 Signaling Genes Predicts Poor Survival Outcome in Glioblastoma Multiforme in a Subtype-Specific Manner
- (2012) Christine W. Duarte et al. PLoS One
- Resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus: Role of type I interferon signaling
- (2012) Megan Moerdyk-Schauwecker et al. VIROLOGY
- The role of Type I interferons in immunoregulation of breast cancer metastasis to the bone
- (2012) Clare Y. Slaney et al. OncoImmunology
- miR-146a suppresses the sensitivity to interferon-α in hepatocellular carcinoma cells
- (2011) Akira Tomokuni et al. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
- Vascular endothelial growth factor-induced elimination of the type 1 interferon receptor is required for efficient angiogenesis
- (2011) H. Zheng et al. BLOOD
- Combination of pegylated IFN- 2b with imatinib increases molecular response rates in patients with low- or intermediate-risk chronic myeloid leukemia
- (2011) B. Simonsson et al. BLOOD
- The Efficacy of Radiotherapy Relies upon Induction of Type I Interferon-Dependent Innate and Adaptive Immunity
- (2011) B. C. Burnette et al. CANCER RESEARCH
- Direct Effects of Type I Interferons on Cells of the Immune System
- (2011) S. Hervas-Stubbs et al. CLINICAL CANCER RESEARCH
- Antitumor activity of a novel small molecule STAT3 inhibitor against a human lymphoma cell line with high STAT3 activation
- (2011) Akiyama INTERNATIONAL JOURNAL OF ONCOLOGY
- IFN- Directly Promotes Programmed Cell Death-1 Transcription and Limits the Duration of T Cell-Mediated Immunity
- (2011) S. Terawaki et al. JOURNAL OF IMMUNOLOGY
- Vesicular Stomatitis Virus Has Extensive Oncolytic Activity against Human Sarcomas: Rare Resistance Is Overcome by Blocking Interferon Pathways
- (2011) J. C. Paglino et al. JOURNAL OF VIROLOGY
- Immune parameters affecting the efficacy of chemotherapeutic regimens
- (2011) Laurence Zitvogel et al. Nature Reviews Clinical Oncology
- Inflammatory signaling compromises cell responses to interferon alpha
- (2011) W-C HuangFu et al. ONCOGENE
- Epigenetic Silencing of IRF7 and/or IRF5 in Lung Cancer Cells Leads to Increased Sensitivity to Oncolytic Viruses
- (2011) Qunfang Li et al. PLoS One
- Interferon-stimulated genes and their antiviral effector functions
- (2011) John W Schoggins et al. Current Opinion in Virology
- Interferon-α as angiogenesis inhibitor: Learning from tumor models
- (2010) Stefano Indraccolo AUTOIMMUNITY
- MicroRNA-21 induces resistance to the anti-tumour effect of interferon-α/5-fluorouracil in hepatocellular carcinoma cells
- (2010) Y Tomimaru et al. BRITISH JOURNAL OF CANCER
- Suppression of SOCS3 increases susceptibility of renal cell carcinoma to interferon-α
- (2010) Shintaro Tomita et al. CANCER SCIENCE
- Alterations of microRNAs and their targets are associated with acquired resistance of MCF-7 breast cancer cells to cisplatin
- (2010) Igor P. Pogribny et al. INTERNATIONAL JOURNAL OF CANCER
- Sustained Molecular Response With Interferon Alfa Maintenance After Induction Therapy With Imatinib Plus Interferon Alfa in Patients With Chronic Myeloid Leukemia
- (2010) Andreas Burchert et al. JOURNAL OF CLINICAL ONCOLOGY
- Positive Regulation of Interferon Regulatory Factor 3 Activation by Herc5 via ISG15 Modification
- (2010) H. X. Shi et al. MOLECULAR AND CELLULAR BIOLOGY
- Resistance to IFN- -Induced Apoptosis Is Linked to a Loss of STAT2
- (2010) A. L. Romero-Weaver et al. MOLECULAR CANCER RESEARCH
- Virus-Induced Unfolded Protein Response Attenuates Antiviral Defenses via Phosphorylation-Dependent Degradation of the Type I Interferon Receptor
- (2009) Jianghuai Liu et al. Cell Host & Microbe
- PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses
- (2009) P T Sobol et al. GENE THERAPY
- Evaluation of an Attenuated Vesicular Stomatitis Virus Vector Expressing Interferon-β for Use in Malignant Pleural Mesothelioma: Heterogeneity in Interferon Responsiveness Defines Potential Efficacy
- (2009) Vassiliki Saloura et al. HUMAN GENE THERAPY
- Down-regulation of type I interferon receptor sensitizes bladder cancer cells to vesicular stomatitis virus-induced cell death
- (2009) Kai-xin Zhang et al. INTERNATIONAL JOURNAL OF CANCER
- Beta-interferon, retinoids and tamoxifen in metastatic breast cancer: Long-term follow-up of a phase II study
- (2009) Recchia ONCOLOGY REPORTS
- Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes
- (2009) H. Cheon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Tumor-Targeted Interferon-α Delivery by Tie2-Expressing Monocytes Inhibits Tumor Growth and Metastasis
- (2008) Michele De Palma et al. CANCER CELL
- Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial
- (2008) Alexander MM Eggermont et al. LANCET
- Inhibition of the IFN-β Response in Hepatocellular Carcinoma by Alternative Spliced Isoform of IFN Regulatory Factor-3
- (2008) Sabrina Marozin et al. MOLECULAR THERAPY
- An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer
- (2008) R. R. Weichselbaum et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now